AI Article Synopsis
- Exposure of MCF-7 breast cancer cells to medroxyprogesterone acetate (MPA) before treatment with adriamycin (ADR) boosted the drug's cytotoxic effects on cell growth.
- Pretreatment with oestradiol (E2) showed similar synergistic effects, while dexamethasone did not enhance ADR's effect.
- Even in MPA-resistant cells, the synergistic benefit of the drug combination was evident, suggesting potential for further clinical trials on this treatment approach.
Article Abstract
Exposure of cultured human breast cancer cells (MCF-7) to medroxyprogesterone acetate (MPA) prior to treatment with adriamycin (ADR) enhanced the effect of the cytotoxic drug on cell yield after further growth of viable cells. Pretreatment with oestradiol (E2) produced similar synergism, but no such effect was observed using dexamethasone. Exposure to ADR before MPA led to an additive effect, but not to synergism. When cells resistant to the growth-inhibitory action of MPA were examined, progestogen/drug synergism could still be demonstrated. We conclude that the effects of ADR, like those of methotrexate and vincristine, can be enhanced by pre-treatment with MPA and that further clinical trials of such a regimen are needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ijc.2910430432 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!